Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1997 Oct;50(5):225–233. doi: 10.1136/mp.50.5.225

Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis.

E Paleolog 1
PMCID: PMC379637  PMID: 9497911

Abstract

Rheumatoid arthritis (RA) is characterised by chronic joint inflammation and infiltration by cells from the blood, especially activated T cells and macrophages, together with formation of new blood vessels. The overgrowth of the synovial lesion results eventually in destruction of cartilage and bone. Cytokines play a major role in RA, both in systemic inflammatory processes, such as induction of acute phase protein synthesis, and in the stimulation of new blood vessel development and recruitment of leucocytes to developing lesions. The focus for the interplay of many cytokines is the endothelium, the lining layer of the vasculature. This is the primary target for circulating mediators, and it controls the traffic of cells and molecules from the bloodstream into underlying tissues. Targeting the action of individual cytokines--for example, using antibody against tumour necrosis factor alpha (TNF alpha), has been shown to be very effective in the treatment of RA. Blockade of TNF alpha activity results in deactivation of the endothelium, manifested as reduced expression of adhesion molecules and chemoattractant cytokines, leading to diminished trafficking of inflammatory cells to synovial joints. In addition anti-TNF alpha decreases circulating levels of the potent angiogenic cytokine VEGF, suggesting that new blood vessel formation, and hence the supply of nutrients to the growing synovial lesion, is also affected. These observations lend further support to the hypothesis that interruption of a component of the cytokine network in RA may modulate disease progression, and point the way towards the development of new therapeutic strategies for the treatment of chronic inflammatory disease states.

Full text

PDF
225

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiello L. P., Pierce E. A., Foley E. D., Takagi H., Chen H., Riddle L., Ferrara N., King G. L., Smith L. E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457–10461. doi: 10.1073/pnas.92.23.10457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aoki S., Imai K., Yachi A. Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol. 1993 Nov;38(5):485–490. doi: 10.1111/j.1365-3083.1993.tb02592.x. [DOI] [PubMed] [Google Scholar]
  3. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 1997 Feb 1;99(3):373–376. doi: 10.1172/JCI119168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blake D. R., Merry P., Unsworth J., Kidd B. L., Outhwaite J. M., Ballard R., Morris C. J., Gray L., Lunec J. Hypoxic-reperfusion injury in the inflamed human joint. Lancet. 1989 Feb 11;1(8633):289–293. doi: 10.1016/s0140-6736(89)91305-6. [DOI] [PubMed] [Google Scholar]
  5. Blann A. D., McCollum C. N., Steiner M., Jayson M. I. Circulating adhesion molecules in inflammatory and atherosclerotic vascular disease. Immunol Today. 1995 May;16(5):251–252. doi: 10.1016/0167-5699(95)80169-3. [DOI] [PubMed] [Google Scholar]
  6. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  7. Brennan F. M., Zachariae C. O., Chantry D., Larsen C. G., Turner M., Maini R. N., Matsushima K., Feldmann M. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol. 1990 Sep;20(9):2141–2144. doi: 10.1002/eji.1830200938. [DOI] [PubMed] [Google Scholar]
  8. Buchan G., Barrett K., Turner M., Chantry D., Maini R. N., Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol. 1988 Sep;73(3):449–455. [PMC free article] [PubMed] [Google Scholar]
  9. Butler D. M., Maini R. N., Feldmann M., Brennan F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw. 1995 Jul-Dec;6(4):225–230. [PubMed] [Google Scholar]
  10. Butler D. M., Malfait A. M., Mason L. J., Warden P. J., Kollias G., Maini R. N., Feldmann M., Brennan F. M. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol. 1997 Sep 15;159(6):2867–2876. [PubMed] [Google Scholar]
  11. Carlos T. M., Harlan J. M. Leukocyte-endothelial adhesion molecules. Blood. 1994 Oct 1;84(7):2068–2101. [PubMed] [Google Scholar]
  12. Carlos T. M., Schwartz B. R., Kovach N. L., Yee E., Rosa M., Osborn L., Chi-Rosso G., Newman B., Lobb R., Rosso M. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood. 1990 Sep 1;76(5):965–970. [PubMed] [Google Scholar]
  13. Cheng S. Y., Huang H. J., Nagane M., Ji X. D., Wang D., Shih C. C., Arap W., Huang C. M., Cavenee W. K. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502–8507. doi: 10.1073/pnas.93.16.8502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chu C. Q., Field M., Abney E., Zheng R. Q., Allard S., Feldmann M., Maini R. N. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol. 1991 Dec;86(3):380–386. doi: 10.1111/j.1365-2249.1991.tb02941.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chu C. Q., Field M., Feldmann M., Maini R. N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1125–1132. doi: 10.1002/art.1780340908. [DOI] [PubMed] [Google Scholar]
  16. Claffey K. P., Robinson G. S. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev. 1996 Jun;15(2):165–176. doi: 10.1007/BF00437469. [DOI] [PubMed] [Google Scholar]
  17. Colville-Nash P. R., Scott D. L. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis. 1992 Jul;51(7):919–925. doi: 10.1136/ard.51.7.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cronstein B. N. Adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol. 1994 May;6(3):300–304. doi: 10.1097/00002281-199405000-00010. [DOI] [PubMed] [Google Scholar]
  19. Cush J. J., Rothlein R., Lindsley H. B., Mainolfi E. A., Lipsky P. E. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. 1993 Aug;36(8):1098–1102. doi: 10.1002/art.1780360810. [DOI] [PubMed] [Google Scholar]
  20. Deleuran B. W., Chu C. Q., Field M., Brennan F. M., Mitchell T., Feldmann M., Maini R. N. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 1992 Oct;35(10):1170–1178. doi: 10.1002/art.1780351009. [DOI] [PubMed] [Google Scholar]
  21. Dvorak H. F., Detmar M., Claffey K. P., Nagy J. A., van de Water L., Senger D. R. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233–235. doi: 10.1159/000236988. [DOI] [PubMed] [Google Scholar]
  22. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  23. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  24. Fava R. A., Olsen N. J., Spencer-Green G., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Senger D. R., Dvorak H. F., Brown L. F. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994 Jul 1;180(1):341–346. doi: 10.1084/jem.180.1.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Feldmann M., Brennan F. M., Maini R. N. Rheumatoid arthritis. Cell. 1996 May 3;85(3):307–310. doi: 10.1016/s0092-8674(00)81109-5. [DOI] [PubMed] [Google Scholar]
  26. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397. [DOI] [PubMed] [Google Scholar]
  27. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1–8. doi: 10.1007/978-3-0348-9006-9_1. [DOI] [PubMed] [Google Scholar]
  28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. doi: 10.1038/nm0195-27. [DOI] [PubMed] [Google Scholar]
  29. Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995 Dec 1;270(5241):1500–1502. doi: 10.1126/science.270.5241.1500. [DOI] [PubMed] [Google Scholar]
  30. Gearing A. J., Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993 Oct;14(10):506–512. doi: 10.1016/0167-5699(93)90267-O. [DOI] [PubMed] [Google Scholar]
  31. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 Aug 9;86(3):353–364. doi: 10.1016/s0092-8674(00)80108-7. [DOI] [PubMed] [Google Scholar]
  32. Haworth C., Brennan F. M., Chantry D., Turner M., Maini R. N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol. 1991 Oct;21(10):2575–2579. doi: 10.1002/eji.1830211039. [DOI] [PubMed] [Google Scholar]
  33. Ikeda E., Achen M. G., Breier G., Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995 Aug 25;270(34):19761–19766. doi: 10.1074/jbc.270.34.19761. [DOI] [PubMed] [Google Scholar]
  34. Issekutz A. C., Issekutz T. B. A major portion of polymorphonuclear leukocyte and T lymphocyte migration to arthritic joints in the rat is via LFA-1/MAC-1-independent mechanisms. Clin Immunol Immunopathol. 1993 Jun;67(3 Pt 1):257–263. doi: 10.1006/clin.1993.1073. [DOI] [PubMed] [Google Scholar]
  35. Issekutz A. C., Meager A., Otterness I., Issekutz T. B. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol. 1994 Jul;97(1):26–32. doi: 10.1111/j.1365-2249.1994.tb06574.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Johnson B. A., Haines G. K., Harlow L. A., Koch A. E. Adhesion molecule expression in human synovial tissue. Arthritis Rheum. 1993 Feb;36(2):137–146. doi: 10.1002/art.1780360203. [DOI] [PubMed] [Google Scholar]
  37. Jorgensen C., Couret I., Canovas F., Bologna C., Brochier J., Reme T., Lipsky P., Sany J. Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol. 1996 Oct;106(1):20–25. [PubMed] [Google Scholar]
  38. Kakimoto K., Nakamura T., Ishii K., Takashi T., Iigou H., Yagita H., Okumura K., Onoue K. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol. 1992 Jul;142(2):326–337. doi: 10.1016/0008-8749(92)90294-y. [DOI] [PubMed] [Google Scholar]
  39. Kansas G. S. Selectins and their ligands: current concepts and controversies. Blood. 1996 Nov 1;88(9):3259–3287. [PubMed] [Google Scholar]
  40. Katsikis P. D., Chu C. Q., Brennan F. M., Maini R. N., Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994 May 1;179(5):1517–1527. doi: 10.1084/jem.179.5.1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Kavanaugh A. F., Davis L. S., Nichols L. A., Norris S. H., Rothlein R., Scharschmidt L. A., Lipsky P. E. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994 Jul;37(7):992–999. doi: 10.1002/art.1780370703. [DOI] [PubMed] [Google Scholar]
  42. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  44. Koch A. E., Burrows J. C., Haines G. K., Carlos T. M., Harlan J. M., Leibovich S. J. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 1991 Mar;64(3):313–320. [PubMed] [Google Scholar]
  45. Koch A. E., Halloran M. M., Haskell C. J., Shah M. R., Polverini P. J. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995 Aug 10;376(6540):517–519. doi: 10.1038/376517a0. [DOI] [PubMed] [Google Scholar]
  46. Koch A. E., Harlow L. A., Haines G. K., Amento E. P., Unemori E. N., Wong W. L., Pope R. M., Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 1994 Apr 15;152(8):4149–4156. [PubMed] [Google Scholar]
  47. Koch A. E., Kunkel S. L., Harlow L. A., Johnson B., Evanoff H. L., Haines G. K., Burdick M. D., Pope R. M., Strieter R. M. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992 Sep;90(3):772–779. doi: 10.1172/JCI115950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Koch A. E., Kunkel S. L., Harlow L. A., Mazarakis D. D., Haines G. K., Burdick M. D., Pope R. M., Walz A., Strieter R. M. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest. 1994 Sep;94(3):1012–1018. doi: 10.1172/JCI117414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Koch A. E., Kunkel S. L., Shah M. R., Hosaka S., Halloran M. M., Haines G. K., Burdick M. D., Pope R. M., Strieter R. M. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol. 1995 Oct 1;155(7):3660–3666. [PubMed] [Google Scholar]
  50. Leeuwenberg J. F., Smeets E. F., Neefjes J. J., Shaffer M. A., Cinek T., Jeunhomme T. M., Ahern T. J., Buurman W. A. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992 Dec;77(4):543–549. [PMC free article] [PubMed] [Google Scholar]
  51. Lobb R. R., Chi-Rosso G., Leone D. R., Rosa M. D., Bixler S., Newman B. M., Luhowskyj S., Benjamin C. D., Dougas I. G., Goelz S. E. Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1. J Immunol. 1991 Jul 1;147(1):124–129. [PubMed] [Google Scholar]
  52. Lobb R., Chi-Rosso G., Leone D., Rosa M., Newman B., Luhowskyj S., Osborn L., Schiffer S., Benjamin C., Dougas I. Expression and functional characterization of a soluble form of vascular cell adhesion molecule 1. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1498–1504. doi: 10.1016/0006-291x(91)91063-i. [DOI] [PubMed] [Google Scholar]
  53. Luscinskas F. W., Gimbrone M. A., Jr Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med. 1996;47:413–421. doi: 10.1146/annurev.med.47.1.413. [DOI] [PubMed] [Google Scholar]
  54. Maini R. N., Elliott M. J., Brennan F. M., Williams R. O., Chu C. Q., Paleolog E., Charles P. J., Taylor P. C., Feldmann M. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 1995 Apr;144:195–223. doi: 10.1111/j.1600-065x.1995.tb00070.x. [DOI] [PubMed] [Google Scholar]
  55. Majewska E., Paleolog E., Baj Z., Kralisz U., Feldmann M., Tchórzewski H. Role of tyrosine kinase enzymes in TNF-alpha and IL-1 induced expression of ICAM-1 and VCAM-1 on human umbilical vein endothelial cells. Scand J Immunol. 1997 Apr;45(4):385–392. doi: 10.1046/j.1365-3083.1997.d01-412.x. [DOI] [PubMed] [Google Scholar]
  56. Mason J. C., Kapahi P., Haskard D. O. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum. 1993 Apr;36(4):519–527. doi: 10.1002/art.1780360412. [DOI] [PubMed] [Google Scholar]
  57. Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994 Feb 10;367(6463):576–579. doi: 10.1038/367576a0. [DOI] [PubMed] [Google Scholar]
  58. Mukhopadhyay D., Tsiokas L., Sukhatme V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995 Dec 15;55(24):6161–6165. [PubMed] [Google Scholar]
  59. Nagashima M., Yoshino S., Ishiwata T., Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol. 1995 Sep;22(9):1624–1630. [PubMed] [Google Scholar]
  60. Oliver S. J., Banquerigo M. L., Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol. 1994 Aug;157(1):291–299. doi: 10.1006/cimm.1994.1223. [DOI] [PubMed] [Google Scholar]
  61. Oliver S. J., Cheng T. P., Banquerigo M. L., Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol. 1995 Dec;166(2):196–206. doi: 10.1006/cimm.1995.9978. [DOI] [PubMed] [Google Scholar]
  62. Paleolog E. M., Aluri G. R., Feldmann M. Contrasting effects of interferon gamma and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor alpha. Cytokine. 1992 Nov;4(6):470–478. doi: 10.1016/1043-4666(92)90007-e. [DOI] [PubMed] [Google Scholar]
  63. Paleolog E. M. Angiogenesis: a critical process in the pathogenesis of RA--a role for VEGF? Br J Rheumatol. 1996 Oct;35(10):917–919. doi: 10.1093/rheumatology/35.10.917. [DOI] [PubMed] [Google Scholar]
  64. Paleolog E. M., Delasalle S. A., Buurman W. A., Feldmann M. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 1994 Oct 15;84(8):2578–2590. [PubMed] [Google Scholar]
  65. Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1082–1091. doi: 10.1002/art.1780390703. [DOI] [PubMed] [Google Scholar]
  66. Peacock D. J., Banquerigo M. L., Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med. 1992 Apr 1;175(4):1135–1138. doi: 10.1084/jem.175.4.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Pigott R., Dillon L. P., Hemingway I. H., Gearing A. J. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992 Sep 16;187(2):584–589. doi: 10.1016/0006-291x(92)91234-h. [DOI] [PubMed] [Google Scholar]
  68. Pober J. S., Gimbrone M. A., Jr, Lapierre L. A., Mendrick D. L., Fiers W., Rothlein R., Springer T. A. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986 Sep 15;137(6):1893–1896. [PubMed] [Google Scholar]
  69. Remmers E. F., Sano H., Wilder R. L. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum. 1991 Dec;21(3):191–199. doi: 10.1016/0049-0172(91)90009-o. [DOI] [PubMed] [Google Scholar]
  70. Saklatvala J., Davis W., Guesdon F. Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):151–157. doi: 10.1098/rstb.1996.0011. [DOI] [PubMed] [Google Scholar]
  71. Sano H., Forough R., Maier J. A., Case J. P., Jackson A., Engleka K., Maciag T., Wilder R. L. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol. 1990 Apr;110(4):1417–1426. doi: 10.1083/jcb.110.4.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sewell K. L., Trentham D. E. Pathogenesis of rheumatoid arthritis. Lancet. 1993 Jan 30;341(8840):283–286. doi: 10.1016/0140-6736(93)92627-6. [DOI] [PubMed] [Google Scholar]
  73. Slowik M. R., De Luca L. G., Fiers W., Pober J. S. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol. 1993 Dec;143(6):1724–1730. [PMC free article] [PubMed] [Google Scholar]
  74. Szekanecz Z., Haines G. K., Lin T. R., Harlow L. A., Goerdt S., Rayan G., Koch A. E. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum. 1994 Feb;37(2):221–231. doi: 10.1002/art.1780370211. [DOI] [PubMed] [Google Scholar]
  75. Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
  76. Tanaka Y., Adams D. H., Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today. 1993 Mar;14(3):111–115. doi: 10.1016/0167-5699(93)90209-4. [DOI] [PubMed] [Google Scholar]
  77. Thomas K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996 Jan 12;271(2):603–606. doi: 10.1074/jbc.271.2.603. [DOI] [PubMed] [Google Scholar]
  78. Tuder R. M., Flook B. E., Voelkel N. F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 1995 Apr;95(4):1798–1807. doi: 10.1172/JCI117858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Wahl S. M., Allen J. B., Hines K. L., Imamichi T., Wahl A. M., Furcht L. T., McCarthy J. B. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest. 1994 Aug;94(2):655–662. doi: 10.1172/JCI117382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Wellicome S. M., Kapahi P., Mason J. C., Lebranchu Y., Yarwood H., Haskard D. O. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1993 Jun;92(3):412–418. doi: 10.1111/j.1365-2249.1993.tb03413.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Zhang Y., Deng Y., Luther T., Müller M., Ziegler R., Waldherr R., Stern D. M., Nawroth P. P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994 Sep;94(3):1320–1327. doi: 10.1172/JCI117451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. el-Gabalawy H., Gallatin M., Vazeux R., Peterman G., Wilkins J. Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Comparison with other adhesion molecules. Arthritis Rheum. 1994 Jun;37(6):846–854. doi: 10.1002/art.1780370612. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES